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Understanding the mechanisms that con-
tribute to the genesis of invasive carcino-
ma from healthy epithelia is a problem of
significance and considerable challenge.
In the epidermis, the most common site
of human cancer, this process involves
disruption of the tightly regulated cycle of
epidermal growth and differentiation,
resulting in hyperproliferation and subse-
quent invasion into dermis. Enter the Ras
GTPase, one of the most widely studied
and important molecules in cancer, which
has the potential to affect epithelial func-
tion and carcinogenesis in numerous and
profound ways (Shields et al., 2000).
Although the involvement of Ras in
human SCC seems likely, given data
from mouse models of SCC (Yuspa,
1998) and the finding that activating Ras
mutations occur in some spontaneous
SCCs (Pierceall et al., 1991), the fact that
expression of active Ras induces growth
arrest in human epidermal cells compli-
cates the nature of its involvement (Dajee
et al., 2003). In principle, the existence of
a secondary mechanism that prevents
Ras-induced growth arrest would liberate
the tumorigenic functions of Ras. Recent
studies from Khavari’s group (Dajee et
al., 2003; Lazarov et al., 2002) validate
this idea and provide insights into the
mechanisms that underlie the formation
of invasive SCC in humans.
Using a model system that involves
the retroviral expression of specific
genes in primary human keratinocytes
and the subsequent use of these cells for
grafting to regenerate human skin on
immune-deficient mice, Khavari’s group
discovered that expression of oncogenic
Ras (Ras Gly12Val mutant) alone
induces growth arrest and graft failure
because it suppresses expression of
CDK4, a cyclin-dependent kinase that
inactivates Rb. However, coexpression of
oncogenic Ras with molecules that
impede Ras-induced growth arrest
results in epidermal carcinoma resem-
bling SCC. Invasive epidermal carcino-
ma resulted from the coexpression of
oncogenic Ras with either CDK4
(Lazarov et al., 2002) or IκBα (Dajee et
al., 2003), a molecule that complexes
with NF-κB and prevents it from entering
the nucleus and mediating transcription.
Interestingly, CDK4 expression appears
to be central to the mechanism of tumori-
genesis in both studies, because IκBα
induces CDK4 expression, providing a
mechanism by which NF-κB inhibition
prevents Ras-mediated growth arrest
(Figure 1).
The results obtained with IκBα are of
particular interest to many in the NF-κB
field, because it had been known that
NF-κB inhibits epidermal proliferation
and that inhibition of NF-κB predisposes
murine skin to tumorigenesis (Dajee et
al., 2003), functions that contrast with
the protumorigenic function of NF-κB
seen in other tumors (Karin et al., 2002).
In fact, expression of IκBα alone in the
graft model induced a mild hyperplasia
substantiating the finding that NF-κB
inhibits epidermal proliferation. One con-
clusion that emerges from their work is
that cooperativity between Ras signaling
and NF-κB function drives the formation
of SCCs: IκBα expression enables epi-
dermal cells to circumvent Ras G1
restraints, and Ras prevents the suscep-
tibility to apoptosis caused by inhibition
of NF-κB function. An unfortunate conse-
quence of these findings is that NF-κB
inhibitors, which are being developed for
cancer therapy, may actually promote
the formation of epidermal carcinomas.
A striking finding in the Khavari
studies is that the epidermal carcinomas
are highly invasive. The mechanisms
involved in the formation of carcinomas
and in the progression to invasive carci-
noma are rather, distinct implying that
the cooperative effects of Ras signaling
and either CDK4 or IκBα expression
transcend cell cycle regulation and alter
other aspects of epithelial function. This
implication is validated by their finding
that a marked decrease in E-cadherin
expression was seen in both the
Ras/CDK4 and Ras/IκBα tumors. Loss
of E-cadherin is known to facilitate an
invasive phenotype by promoting an
epithelial-mesenchymal transition, a
process that can be driven by Ras (Oft et
al., 2002). Other changes observed in
these tumors include increased expres-
sion of matrix metalloproteases and
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Although the genesis of invasive squamous cell carcinoma (SCC) from stratified epithelia of the skin is considered to be a
complex, multistage process, recent work on human epidermis reveals that sustained Ras signaling coupled with suppres-
sion of Ras-induced growth arrest is sufficient to drive the entire process and that the α6β4 integrin and its laminin 5 ligand
are essential components of this process.
Figure 1. The genesis of invasive epidermal
cancer
Expression of oncogenic Ras in human epi-
dermal cells induces growth arrest by a
mechanism that involves NF-κB induction
and CDK4 expression. Circumvention of Ras-
induced growth arrest either by expression of
CDK4 or blockade of NF-κB function by
expression of IκBα liberates the oncogenic
functions of Ras and results in invasive carci-
noma resembling SCC. Tumors that form
invade deeply into the dermis. The α6β4 inte-
grin is expressed in basal epidermal cells,
where it anchors the epidermis to the under-
lying basement membrane by engaging
laminin 5. Expression of α6β4 increases signifi-
cantly in SCC, and both α6β4 and laminin 5
are necessary for tumor formation.
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VEGF, changes that are also associated
with invasive carcinoma. Although these
recent studies have focused on cell cycle
regulation, a challenge ahead is to
establish mechanistic links between Ras
signaling, IκBα or CDK4 expression, and
specific functions associated with inva-
sion. A key issue in this direction is
whether IκBα, for example, contributes
to invasive functions directly. Convincing
data provided by Dajee et al. (2003) indi-
cate that the effects of IκBα expression
are limited to NF-κB inhibition. Unless
NF-κB mediates the transcription of
genes that are “antiinvasive,” a likely
assumption is that the invasive pheno-
type observed in the oncogenic
Ras/IκBα tumors is the result of sus-
tained Ras signaling. One potentially
fruitful line of research would be to inves-
tigate endogenous TGF-β signaling in
the oncogenic Ras/IκBα tumors, given
that elevation of Ras and Smad2 levels is
sufficient to generate invasive SCC in
mice (Oft et al., 2002).
Another important finding reported
by Dajee et al. (2003) is the necessity of
the α6β4 integrin for epidermal carcino-
ma formation. This integrin is essential
for the integrity of the epidermis
because it engages laminin 5 in the
basement membrane that separates the
epidermis from the dermis, and it pro-
vides a link to the intermediate filament
cytoskeleton in epidermal cells in rigid
structures termed hemidesmosomes
(Mercurio and Rabinovitz, 2001). It has
been implicated also in epidermal prolif-
eration (Mainiero et al., 1997). In addi-
tion, many studies have established a
role for α6β4 in more dynamic functions
associated with invasive carcinoma,
including migration and survival
(Mercurio and Rabinovitz, 2001; Shaw
et al., 1997), findings that are consistent
with the fact that expression of α6β4
increases markedly in SCC but not in
basal cell carcinomas (Rossen et al.,
1994), which also originate from epider-
mal cells but are relatively nonaggres-
sive. Given these prior studies, their
observation that antibodies specific for
either α6β4 or laminin 5 prevent the gen-
esis of invasive SCC is reassuring. In a
more definitive experiment, Dajee et al.
(2003) observed that keratinocytes defi-
cient in the expression of either the β4
subunit or laminin 5 (isolated from
patients with blistering skin diseases)
were unable to form tumors upon
expression of oncogenic Ras/IκBα, but
expression of the respective genes
restored their ability to form invasive
tumors. These latter data provide the
most definitive evidence to date for the
involvement of α6β4 in the genesis of
invasive carcinoma. It will be informative
to discern how the multiple functions of
α6β4 (e.g., proliferation, migration, sur-
vival) contribute to the formation of inva-
sive epidermal carcinomas.
Despite the findings that activating
Ras mutations occur is some sponta-
neous SCCs and that IκBα expression is
increased is some SCCs compared to
normal epidermis, Dajee et al. (2003)
indicate correctly that these specific
alterations may not account for the for-
mation of most SCCs. Rather, they posit
that “these proteins may engage pro-
grams of carcinogenesis that are acces-
sible to several oncogenic factors.” One
could postulate that alterations in the
expression or activation of Ras effectors
contribute to SCC. In this direction, for
example, it is worth noting that a high fre-
quency of activating mutations in B-Raf,
a Ras effector, occurs in premalignant
and malignant melanomas (Pollock et
al., 2003). Nonetheless, the recent find-
ings of the Khavari group substantiate
the central role of the Ras pathway in the
genesis of invasive epidermal carcino-
ma, and they reveal the necessity of
additional mechanisms such as NF-κB
inhibition that release Ras-mediated
growth arrest. They also present com-
pelling evidence for the involvement of
the α6β4 integrin and one of its laminin
ligands in epidermal carcinogenesis.
Future studies that link components of
the Ras pathway to specific aspects of
epidermal transformation and invasion
and that define the interactions between
Ras and α6β4 more rigorously should be
rewarding.
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